KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CareDx (CDNA) Receivables (2016 - 2026)

CareDx's Receivables history spans 14 years, with the latest figure at $44.6 million for Q1 2026.

  • On a quarterly basis, Receivables fell 37.63% to $44.6 million in Q1 2026 year-over-year; TTM through Mar 2026 was $44.6 million, a 37.63% decrease, with the full-year FY2025 number at $42.6 million, down 34.02% from a year prior.
  • Receivables hit $44.6 million in Q1 2026 for CareDx, up from $42.6 million in the prior quarter.
  • Over the last five years, Receivables for CDNA hit a ceiling of $71.5 million in Q1 2025 and a floor of $42.6 million in Q4 2025.
  • Historically, Receivables has averaged $59.8 million across 5 years, with a median of $64.6 million in 2024.
  • The widest YoY moves for Receivables: up 45.93% in 2022, down 99.78% in 2022.
  • Tracing CDNA's Receivables over 5 years: stood at $66.3 million in 2022, then decreased by 23.0% to $51.1 million in 2023, then rose by 26.53% to $64.6 million in 2024, then crashed by 34.02% to $42.6 million in 2025, then rose by 4.59% to $44.6 million in 2026.
  • Business Quant data shows Receivables for CDNA at $44.6 million in Q1 2026, $42.6 million in Q4 2025, and $47.8 million in Q3 2025.